Sarcopenia as a Predictor of Survival Among Patients With Organ Metastatic Cervical Cancer.
Nobuhisa YoshikawaAkira ShirakawaKosuke YoshidaSatoshi TamauchiShiro SuzukiFumitaka KikkawaHiroaki KajiyamaPublished in: Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition (2020)
High PMI was determined to be a favorable prognostic factor for patients with organ metastatic cervical cancer. Moreover, patients with organ metastatic cervical cancer who have a PMI > 3.72 cm2 /m2 may benefit from CCRT as an initial treatment.